<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="623">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542967</url>
  </required_header>
  <id_info>
    <org_study_id>047/2020</org_study_id>
    <nct_id>NCT04542967</nct_id>
  </id_info>
  <brief_title>Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease</brief_title>
  <acronym>PC-COVID-HCM</acronym>
  <official_title>Convalescent Plasma as a Treatment for Patients With Severe COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Central Militar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Central Militar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there is no specific treatment or vaccine for SARS-CoV-2 available, some drugs are
      being investigated as treatment, but the effect is unknown. A strategy and other method used
      before, in coronavirus pandemic (SARS-CoV in 2003 and MERS-CoV in 2012), was the use of
      immune (convalescent) plasma. Passive administration of antibodies through convalescent
      plasma transfusion may offer the only short-term strategy available to confer immediate
      immunity and being a relative immediately resource available for treat COVID-19 disease. This
      research proposes the passive administration of antibodies through the transfusion of
      convalescent plasma, in patients with severe COVID-19 disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized clinical trial comparing administration convalescent plasma to standard therapy
      for severe COVID-19 disease. Patients will be randomized 1:1 in a single blind study. The
      patients with SARS-CoV-2 PCR confirmed infection with pulmonary infiltrates and hypoxemia
      will be screened and invited to participate. Our primary outcomes will be disease progression
      and mortality, evaluate of ordinal Scale for Clinical Improvement and. (WHO)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression</measure>
    <time_frame>Up to 30 days later from study entry</time_frame>
    <description>Change in ordinal Scale for Clinical Improvement (WHO). The progression disease, its the change in the severity score; a bigger number to the obtained after randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Side effects</measure>
    <time_frame>Up to 30 days later from study entry</time_frame>
    <description>Side effects associated with the administration of convalescent plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 30 days later from study entry</time_frame>
    <description>Any cause of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory improvement</measure>
    <time_frame>10 days</time_frame>
    <description>Change in partial pressure of arterial Oxygen to Fraction of inspired Oxygen ratio (PaO2/FiO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>10 days</time_frame>
    <description>Change in oxygen saturation levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute adverse events (AAE)</measure>
    <time_frame>After receiving intervention, an average time one hour, until 24 hours after administration.</time_frame>
    <description>Transfusion reactions during transfusion.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammatory biomarkers (D dimer)</measure>
    <time_frame>10 days</time_frame>
    <description>Change in pro-inflammatory biomarkers (D dimer μg/l)</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory biomarkers (Ferritin)</measure>
    <time_frame>10 days</time_frame>
    <description>Change in pro-inflammatory biomarkers ( Ferritin μg/L )</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory biomarkers (CPR)</measure>
    <time_frame>10 days</time_frame>
    <description>Change in pro-inflammatory biomarkers, C-reactive protein ( CPR mg/L )</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory biomarkers (LDH)</measure>
    <time_frame>10 days</time_frame>
    <description>Change in pro-inflammatory biomarkers, lactate dehydrogenase ( LDH UI/L)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Severe COVID-19 Disease</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>They will receive the standard care for critically ill inpatients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Convalescent plasma group.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>They will receive standard care for patients with severe COVID-19 disease and convalescent plasma disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological</intervention_name>
    <description>An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.
If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out.</description>
    <arm_group_label>Convalescent plasma group.</arm_group_label>
    <other_name>Convalescent plasma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  O2 saturation &lt;93%

          -  Radiographic evidence of moderate pneumonia according to Rale's classification.

          -  Acute respiratory distress syndrome (PaO2 / FiO2 &lt;300 or SpO2 / FiO2 ≤ 315)

          -  Autorization to participate in the study and have informed consent letter, signed by
             the patient or the person responsible for the patient in case of critical patients
             (intubated)

        Exclusion Criteria:

          -  Pregnant patients

          -  History of transfusion reactions

          -  Patients with congestive heart failure

          -  Patients with a history of chronic kidney failure on dialysis

          -  Patients with multiple organ failure

          -  Patients who does not accept or agree with the treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen G Torres, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Central Militar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmen G Torres, MD</last_name>
    <phone>52015521221100</phone>
    <phone_ext>1520</phone_ext>
    <email>dragabytorresalarcon@icloud.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Blanca E Cid Dominguez, MD</last_name>
    <phone>52015521221100</phone>
    <phone_ext>1520</phone_ext>
    <email>becid2008@hotmail.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Central Militar</name>
      <address>
        <city>Mexico City</city>
        <zip>11200</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen G Torres Alarcón, MD</last_name>
      <phone>2015521221100</phone>
      <phone_ext>1520</phone_ext>
      <email>&quot;dragabytorresalarcon@icloud.com&quot; &lt;dragabytorresalarcon@icloud.com&gt;</email>
    </contact>
    <contact_backup>
      <last_name>Blanca E Cid Dominguez</last_name>
      <phone>2015521221100</phone>
      <phone_ext>1520</phone_ext>
      <email>becid2008@hotmail.es</email>
    </contact_backup>
    <investigator>
      <last_name>Cesar R Cañete Ibáñez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos M Muñoz Arce, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irving I Morales Pogoda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriela Ramírez Galindo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Blanca E Cid Dominguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deniria A Rugerio Trujillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Max J Martínez Utrera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miriam S Ramírez Valdez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guadalupe Maza de la Torre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liliana Bonola Gallardo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose L Hernandez Perdomo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel A Sandoval López, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/32109013/</url>
    <description>Clinical Characteristics of Coronavirus Disease 2019 in China</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/32052466/</url>
    <description>Potential interventions for novel coronavirus in China: A systematic review</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/15616839/</url>
    <description>Use of convalescent plasma therapy in SARS patients in Hong Kong</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV2</keyword>
  <keyword>Convalescent Plasma</keyword>
  <keyword>Severe Acute Respiratory Syndrome</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to make IPD still not decided and would need approval by regulatory authorities</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>PRIOR APPLICATION</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

